SDH is a protein that is based in the mitochondria. Its loss causes a major energy and metabolic crisis. Despite this, some types of cells can 'benefit' from the loss of SDH and continue to [...]
Have you researched the subject, but would really rather hear the perspective only a fellow patient can provide? Listen to the informative webcast recording from Wednesday, December 13th from Dr. Nikhil Guhagarkar MDS, who addressed these [...]
On Monday, November 13th, The Life Raft Group in collaboration with Deciphera Pharmaceuticals hosted a webcast which provided patients with an overview of the DCC-2618 GIST program, including enrollment updates from the ongoing [...]
Columbia University Medical Center, New York-Presbyterian and the Life Raft Group have entered into a collaborative effort to advance research to find a cure for GIST using a novel therapeutic approach and patient-driven data. [...]
Dr. Anthony Boral, Chief Medical Officer of Blueprint Medicines, provided an update on the clinical development of BLU-285, an investigational medicine being developed for patients with advanced GIST. The presentation included an [...]
The Life Raft Group presented an informative webcast on Fertility, Pregnancy and GIST. Presented on March 30, 2017 Learn about: Impact of cancer treatment on fertility Options to preserve eggs and sperm [...]
The Life Raft Group presented an informative webcast on Gene Fusions. Presented on February 22, 2017 Learn about: Recently identified gene fusions in GIST Populations they target Current studies that may identify them How they [...]
On September 28, 2016, the Life Raft Group was pleased to have Melissa Simpson, Senior Program Manager in the Center for Benefits Access at the National Council on Aging share her knowledge and insight [...]
On September 19, 2016 the Life Raft Group was pleased to have Dr. Benjamin D. Humphreys, Chief of the Division of Nephrology at Washington University in St. Louis School of Medicine, share his knowledge [...]
On February 1, 2016, the commercial launch of the generic version of imatinib mesylate (Gleevec), originally for CML (Chronic Myeloid Leukemia), was approved by the FDA and became available for the first time [...]
